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Abstract Objective Anticoagulation management in patients with atrial fibrillation (AF) and
impaired renal function is challenging. This study aimed to evaluate anticoagulation
prescription patterns in relation to renal function and to describe 2-year clinical
outcomes among dabigatran users.
Methods Global Registry on Long-Term Oral Antithrombotic Treatment in Patients
with Atrial Fibrillation (GLORIA-AF) is an international, prospective, and observational
study program involving patients with newly diagnosed AF at risk for stroke. Prescrip-
tion patterns were assessed by creatinine clearance (CrCl) at enrollment. Dabigatran
users were followed for 2 years. Clinical outcomes were standardized for stroke and
bleeding risk, based on CHA2DS2-VASc and HAS-BLED scores, with missing values
imputed.
 Joint senior authors and co-Chairs of the GLORIA-AF Registry
Program.
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Some degree of renal impairment is estimated to be present
in approximately 35% of patients with atrial fibrillation (AF)
and is associatedwith increased riskof both thromboembolic
and bleeding events.1–3 Consequently, oral anticoagulation
management is challenging and often requires dose adjust-
ment. Suboptimal use of vitamin K antagonists (VKAs) or
non-vitamin K antagonists (NOACs) increase the risk of
stroke and systemic embolism.4–6How renal function affects
anticoagulation prescription practice is unclear.
All NOACs undergo some degree of renal clearance. Conse-
quently, diminished renal function could lead to drug accu-
mulation and increase the risk of bleeding complications.
Clinical practice guidelines recommend caution regarding
NOAC use in patients with renal dysfunction.7,8 Rivaroxaban,
apixaban, and edoxaban, but not dabigatran, are approved in
Europe for use in patientswith severe renal impairment (i.e., a
creatinineclearance [CrCl] of<30mL/min).8Thisdiffers for the
United States, where dabigatran is only contraindicated below
a CrCl of 15mL/min due to the available dose of 75mg twice
daily.9 Moreover, in the United States, no contraindications
exist for rivaroxaban and apixaban based on renal function.
Lowerdoses, however, are recommended forCrCl50mL/min
(rivaroxaban) and serum 1.5mg/dL (apixaban).10,11
A meta-analysis demonstrated fewer thromboembolic
andmajor bleeding events in patients withmild or moderate
renal impairment (CrCL¼30–79mL/min) treated with
NOACs than with VKAs, although there is considerable
heterogeneity across studies.12 Moreover, the effectiveness
and safety of NOACs in patients with a CrCl <30mL/min has
not been established.
The purposes of this studywere to evaluate anticoagulation
prescription patterns in relation to baseline renal function for
patients with AF enrolled in phase II of the Global Registry on
Long-Term Oral Antithrombotic Treatment in Patients with
Atrial Fibrillation (GLORIA-AF) study and to describe clinical
outcomes over 2 years in patients who received dabigatran
etexilate.
Methods
Patients and Study Design
The study design and baseline characteristics of patients
enrolled in the GLORIA-AF Registry Program have been
described previously.13,14 In short, GLORIA-AF is an interna-
tional, prospective, observational and study program, run in
three phases, enrolling consecutive adult patients with
nonvalvular AF who were newly diagnosed in a variety of
clinical settings between 2010 and 2017. The study excluded
patientswithmechanical heart valves, previous VKA therapy
for >60 days, AF due to a generally reversible cause, and life
expectancy <1 year. During phase II of the program (patient
enrollment from 2011 to 2014), cross-sectional data were
collected, regardless of treatment, and patients prescribed
dabigatran were followed for up to 2 years, with visits
scheduled around 3, 6, 12, and 24 months. Dabigatran was
prescribed at the discretion of treating physicians in avail-
able doses (150, 110, and 75mg twice daily, depending on
the country and local label). Patients who took at least one
dose of dabigatran were included in the outcome event
analysis. Final phase II results have been recently been
published.15 In the present report, phase II data were evalu-
ated in relation to baseline renal function. GLORIA-AF was a
noninterventional study; hence, prescription requirements
were not stipulated in the protocol.
Study Aim
The aims of the study were to evaluate anticoagulation pre-
scriptionpatterns inpatientswithdifferent CrCl categories and
todescribe2-year incidence ratesof stroke,majorbleeding, and
death for patients treated with dabigatran according to CrCl.
The CrCl was calculated according to Cockcroft-Gault formula:
CrCl (mL/min)¼ (140 age)weight (kg) (0.85 if female)/
(72 serum creatinine concentration). Renal impairment
was categorized according to international guidelines as no
impairment (CrCl80mL/min), mild impairment (CrCl¼50–
79mL/min), moderate impairment (CrCl¼30–49mL/min),
and severe impairment (CrCl<30mL/min).16,17
Results Baseline CrCl values were available for 12,056 of 15,308 eligible patients
(79%). With declining renal function, prescriptions increased for vitamin K antagonists
(VKAs) and decreased for dabigatran (30–47% and 34–12%, respectively). The pre-
scription of other non-vitamin K antagonists remained similar across CrCl groups
(14–19%). In 4,873 dabigatran users, standardized stroke rates were low across all CrCl
groups; 0.58/100 patient-years (95% confidence interval [CI]: 0.30–0.90) in CrCl
80mL/min, 0.85 (95% CI: 0.48–1.21) in CrCl 50 to 79mL/min, and 0.33 (95% CI:
0.06–1.11) in CrCl 30 to 49mL/min. Similarly, major bleeding rates were low and
numerically increased with declining renal function (0.68/100 patient-years, 95% CI:
0.39–1.03; 0.92, 95% CI: 0.58–1.32; and 1.26, 95% CI: 0.66–1.97, respectively).
Conclusion In patients with AF, VKA prescriptions increased and dabigatran pre-
scriptions decreased with declining renal function. Rates of stroke and major bleeding
in dabigatran patients remained low across the categories of renal impairment.
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Outcomes
Only patients taking dabigatran were followed for the occur-
rence of clinical outcomes. Stroke was defined as the acute
onset of a focal neurologic deficit of presumed vascular origin
24hours or more or resulting in death. Stroke type was
categorized as ischemic, hemorrhagic, or uncertain (based
on computed tomography or magnetic resonance scanning,
or autopsy). Major bleeding was defined according to criteria
of the International SocietyonThrombosis andHaemostasis.18
Deaths were classified as vascular (including bleeding) and
nonvascular due to other specified causes (e.g.,malignancy) or
unknown cause.
Statistical Analysis
Baseline characteristics of patients were examined by cate-
gories of renal function. Continuous variables are presented
as the means (standard deviation [SD]) or medians (with
interquartile range [IQR]) and categoric variables as frequen-
cy (n) and percent (%).
For the derivation of incidence rates of dabigatran out-
come incidence rates, the risk period began with treatment
initiation and ended with permanent dabigatran discontin-
uation, which was defined by treatment stop þ3 days,
substitution of another anticoagulant treatment, or study
completion. Incidence rateswere calculated based on time to
first event of interest. Patients prescribed dabigatranwho did
not take at least one dose (n¼14) were excluded.
To adjust for potential confounding, incidence rates were
standardized by HAS-BLED score using two categories, less
than 2 or2, andCHA2DS2-VASc scores using three categories,
<3, 3, and4, for a total of six categories when stratifying by
both variables. Standardization was accomplished by obtain-
ing aweighted average of the stratum-specific incidence rates,
using weights equal to the total number of patient years for all
patients in that stratum. Because only a small number of
patients had a CrCl <30mL/min, rates were not reported for
that category. HAS-BLED and CrCl had noticeable proportions
of patients taking dabigatran with missing data (10 and 23%,
respectively); multiple imputation using chained equations
was applied to address this.19 The imputation model was
constructed upon 54 clinically relevant baseline patient char-
acteristic variables and thenumberof imputation is 20. TheCIs




Baseline characteristics by CrCl for both the entire population
as well as dabigatran users are displayed in►Table 1. Baseline
creatinine levels were available for 12,056 of 15,308 eligible
patients (79%). For the entire population, a total of 5,116 of
15,308 patients (33%) had CrCl 80mL/min; 4,714 (31%) had
CrCl 50 to 79mL/min; 1,805 (12%) had CrCl 30 to 49mL/min,
430 (3%) had CrCl <30mL/min; and 3,243 (21%) had missing
values. Patients with a CrCl 80mL/min were younger
(6310 years) than those with CrCl 50 to 79; 30 to 49; or
<30mL/min (748, 807, 8011, respectively), or those
with unknown CrCl values (7111 years). Most patients had
paroxysmal AF (51–56%, depending on CrCl category),
followed by persistent (35–37%) and permanent AF (8–14%).
As expected, the mean CHA2DS2-VASc score increased with
declining renal function, ranging from 2.6 (SD¼1.3) in
patients with a CrCl 80mL/min to 4.7 (1.5) in patients with
a CrCl<30mL/min. A similar trendwas observed for themean
HAS-BLED score, ranging from 1.1 (SD¼0.9) to 2.0 (1.0).
Patients treated with dabigatran had baseline character-
istics similar to the overall GLORIA-AF population. Of 4,873
patients prescribed dabigatran, 3,759 (77%) had creatinine
measurements available at baseline. A total of 1,743 of 4,873
(36%) had CrCl 80mL/min, 1,488 (31%) had CrCl 50 to
79mL/min, 476 (10%) had CrCl 30 to 49mL/min, and 52
(1%) had CrCl <30mL/min.
Anticoagulation Prescription
At baseline, of all patients with CrCl 80mL/min (n¼5,116),
most were prescribed dabigatran (n¼1,743; 34%) or a VKA
(n¼1,534; 30%), followed by rivaroxaban (n¼647; 13), anti-
platelet therapy (n¼592; 12%), no antithrombotic treatment
(n¼389;8%)andapixaban(n¼188;3.7%).Withdecliningrenal
function, prescription rates increased forVKAanddecreased for
dabigatran (30–47% and 34–12%, respectively; ►Fig. 1). Of the
52 patients taking dabigatran with CrCl <30mL/min, 41 (79%)
were treatedwith the 150 or 110mg twice daily dosage, and 11
(21%) received a75mg twice-daily dose. Elevenpatients receiv-
ing the 75mg twice-daily dose were all located in the United
States. Among all dabigatran patients, 0.9% (n¼41) received
dabigatran 150 and 110mg BID and had a CrCl <30mL/min,
constituting a contraindication. Prescription rates for other
NOACs were similar across renal function strata (9.3–13% for
rivaroxaban and 3.5–6.5% for apixaban, depending on CrCl). As
renal function decreased, prescription of other NOAC standard
doses decreased and use of low doses increased, although
contraindications due to CrCl were not further assessed. The
dabigatran standard dose (150mg twice daily) was prescribed
more frequently in patients with normal renal function (72%)
than for thosewithCrCl 50 to79 (45%) or30 to49mL/min (20%)
(►Table 2). The prescription rate ofantiplatelet orno treatment
was consistent across the renal function strata (19–23%,
depending on CrCl).
Clinical Outcomes
Clinical outcomes in dabigatran-treated patients are shown
in ►Table 3. The standardized incidence rates for stroke were
0.58/100patient-years (95%confidence interval [CI]: 0.30–0.90)
for CrCl80mL/min, 0.85/100 patient-years (95% CI: 0.51–1.2)
for CrCl 50 to 79mL/min, and 0.33/100 patient-years (95% CI:
0.06–1.1) forCrCl30 to49mL/min.The incidencerates formajor
bleedingwere0.68/100patient-years (95%CI: 0.39–1.0) forCrCl
80mL/min, 0.92/100 patient-years (95% CI: 0.58–1.3) for CrCl
50 to 79mL/min, and 1.26 (95% CI: 0.66–2.0) for CrCl 30 to
49mL/min. The rates for all-cause death were highest in
patients with a CrCl 30 to 49mL/min (4.5/100 patient-years;
95%CI: 3.1–6.3), followedbypatientswithCrCl 50 to79mL/min
(2.6/100 patient-years; 95% CI: 2.0–3.3) and patients with CrCl
80mL/min (1.6/100 patient-years; 95% CI: 1.1–2.2).
TH Open Vol. 5 No. 1/2021 © 2021. The Author(s).
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Discussion
The first main finding of this large global prospective study is
that VKA prescription increased and dabigatran prescription
decreasedwithdeclining renal function.Noclear trendcouldbe
observed for the prescription of other NOACs and antiplatelet/
no treatment groups. Second, less than 1% of dabigatran users
were prescribed the contraindicated 150 and 110mg twice-
daily dosages when their CrCl was <30mL/min. Third, among
dabigatran users, the estimated rates of stroke and major
bleeding were low across all CrCl categories.
Consistent with the EURObservational Research Program:
the Heart Failure Pilot Survey on patients with AF (EORP-AF
Pilot), nearly 60% of enrolled patients had a CrCl 30 to
79mL/min and 4% had a CrCl <30mL/min.21 Patients with
declining renal function were older and had a higher risk of
stroke (CHA2DS2-VASc score2) and bleeding risk (HAS-
BLED3). This might have led to a decrease in dabigatran
prescriptions, although both the 150 and 110mg twice daily
doses have been found to be safe in patients with a CrCl 30 to
79mL/min.22,23 Conversely, VKA prescriptions increased,
with the highest incidence of 47% in patients with a CrCl
<30mL/min. Consistent with other studies, the use of the
dabigatran 150 and 110mg twice daily doses in patientswith
a CrCl <30mL/min was less than 1%, indicating that contra-
indicated dabigatran use is rare in clinical practice.24,25 For
other NOACs, similar prescription rateswere observed across
CrCl groups, which is probably related to label differences
(i.e.,<15mL/min for rivaroxaban, edoxaban, and apixaban in
the European Union, and no contraindications for rivarox-
aban and apixaban in the United States). Moreover, the
enrollment periodmust be taken into account. As dabigatran
was the only NOAC approved in the European Union during
the first year of study enrollment, higher number of dabiga-
tran prescriptions are included in this assessed cohort as
compared with other NOACs.
We found low rates of stroke (rate estimates range from
0.46 to 0.96/100 patient-years) and major bleeding (rate
estimates range from 0.72 to 2/100 patient-years) across
all CrCl categories with wide and overlapping confidence
intervals. These rates are consistent with those observed in
the EORP-AF Pilot registry inwhich the 1-year rates of stroke
and major bleeding were similar across different renal
groups.21 However, although not directly comparable, the
RE-LY trial reported increasing stroke, systemic embolism,
andmajor bleeding incidenceswith declining renal function,
with highest risk estimates in patients with a CrCL 30 to
49mL/min and lowest in those with normal renal function,
including patients using VKA.23,26 Importantly, the RE-LY
study was a randomized trial without specified dose reduc-
tions and thereby evaluated both dabigatran 150 and 110mg
twice daily doses, independent of CrCl. Conversely, in our
study, dosing was individualized based on patient character-
istics and physician and/or patient preferences, including the
Fig. 1 Antithrombotic prescription patterns according to CrCl in GLORIA-AF. Numbers are percentages. CrCl in mL/min. AP, antiplatelet therapy;
CrCl, creatinine clearance; VKA, vitamin K antagonist.
TH Open Vol. 5 No. 1/2021 © 2021. The Author(s).
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perceived bleeding risk. Therefore, our findings emphasize
that dabigatran can safely be used in patients with mild-to-
moderate impairment. Of note, in the ongoing phase III of
GLORIA-AF follow-up data will be collected from VKA-
treated patients, allowing for future comparison of safety
and effectiveness.13
Limitations
This study has several limitations. First, CrCl values were
missing in 21% of patients andwere imputed for the outcome
analyses. Second, due to broad inclusion of many centers and
countries in this global registry, slight differences in NOAC
labels existed regarding CrCl, which might have influenced
the prescription pattern. Third, while we standardized for
CHADS-VASc and HAS-BLED scores, other differences in
baseline characteristics CrCl groups may not adequately
have been captured. Finally, we assessed renal function at
baseline and did not assess changes in renal function over the
follow-up period.
In conclusion, in contrast to VKA, dabigatran prescription
decreased with declining renal function and was rare in
patients with severe renal impairment. Further, in dabiga-
tran-treatedpatients, the estimated rates of stroke andmajor
bleeding were lowacross the categories of renal impairment.
Note
This study is registered with ClinicalTrials.gov with iden-
tifier no. NCT01468701 (http://www.clinicaltrials.gov).
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Abbreviations: CI, confidence interval; CrCl, creatinine clearance.
Note: Patients with CrCl <30mL/min were omitted from this analysis due to low numbers. Standardized incidence rates were calculated with all
missing HAS-BLED and CrCl values imputed.
aIncludes hemorrhagic, ischemic strokes, and strokes of unknown origin.
TH Open Vol. 5 No. 1/2021 © 2021. The Author(s).
Anticoagulants and Renal Function in GLORIA-AF van der Wall et al. e41
HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb,
Johnson & Johnson, and Pfizer. K.J.R. is an employee of RTI
Health Solutions, an independent nonprofit research or-
ganization that works with government agencies and
pharmaceutical companies. C.T., M.P., K.Z., L.R.F., and S.L.
are employees of Boehringer Ingelheim. G.Y.H.L. has been
a consultant for Bayer/Janssen, Boehringer Ingelheim,
Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Medtronic,
Novartis, and Verseon; and speaker for Bayer, Boehringer
Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo,
and Medtronic. M.V.H. has received honoraria for pre-
sentations and research grants from Actelion Pharma-
ceuticals, Bayer HealthCare, Boehringer Ingelheim,
GlaxoSmithKline, and Pfizer.
References
1 Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of
antithrombotic therapy in patients with atrial fibrillation and
chronic kidney disease: a nationwide observational cohort study.
J Am Coll Cardiol 2014;64(23):2471–2482
2 Kooiman J, van de Peppel WR, van der Meer FJ, Huisman MV.
Incidence of chronic kidney disease in patients with atrial fibril-
lation and its relevance for prescribing new oral antithrombotic
drugs. J Thromb Haemost 2011;9(08):1652–1653
3 Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial
fibrillation with chronic kidney disease. N Engl J Med 2012;367
(07):625–635
4 Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and
effectiveness of warfarin in Medicare beneficiaries with atrial
fibrillation. Stroke 2006;37(04):1070–1074
5 Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of
prescribing dabigatran etexilate and rivaroxaban in patients
with nonvalvular atrial fibrillation: a prospective study. Ann
Pharmacother 2014;48(10):1258–1268
6 Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by
patients with atrial fibrillation in Germany. Adherence to guide-
lines, causes of anticoagulation under-use and its clinical out-
comes, based on claims-data of 183,448 patients. Thromb
Haemost 2012;107(06):1053–1065
7 January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused
Update of the 2014 AHA/ACC/HRS Guideline for the Management of
Patients With Atrial Fibrillation: a Report of the American College of
Cardiology/AmericanHeartAssociationTaskForceonClinicalPractice
Guidelines and the Heart Rhythm Society in Collaboration With the
Society of Thoracic Surgeons. Circulation 2019;140(02):e125–e151
8 Steffel J, Verhamme P, Potpara TS, et al;ESC Scientific Document
Group. The 2018 European Heart Rhythm Association Practical
Guideon theuseof non-vitaminK antagonist oral anticoagulants in
patientswith atrialfibrillation. EurHeart J 2018;39(16):1330–1393
9 Food and Drug Administration (FDA) 2015Prescribing Informa-
tion, Pradaxa. Accessed June 2020 at: https://www.accessdata.
fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf
10 Food and Drug Administration (FDA) 2012Prescribing Informa-
tion, Eliquis. Accessed June 2020 at: https://www.accessdata.
fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
11 Food and Drug Administration (FDA) 2020Prescribing Informa-
tion, Xarelto. Accessed June 2020 at: https://www.accessdata.
fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf
12 Raccah BH, Perlman A, Danenberg HD, Pollak A, Muszkat M,
Matok I. Major bleeding and hemorrhagic stroke with direct
oral anticoagulants in patients with renal failure: systematic
review and meta-analysis of randomized trials. Chest 2016;149
(06):1516–1524
13 Huisman MV, Lip GY, Diener HC, et al. Design and rationale of
Global Registry on Long-Term Oral Antithrombotic Treatment in
Patients with Atrial Fibrillation: a global registry program on
long-term oral antithrombotic treatment in patients with atrial
fibrillation. Am Heart J 2014;167(03):329–334
14 Huisman MV, Rothman KJ, Paquette M, et al;GLORIA-AF Inves-
tigators. Antithrombotic treatment patterns in patients with
newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF
Registry, Phase II. Am J Med 2015;128(12):1306–13.e1
15 Mazurek M, Teutsch C, Diener HC, et al;GLORIA-AF Investigators.
Safety and effectiveness of dabigatran at 2 years: final outcomes
from phase II of the GLORIA-AF registry program. Am Heart J
2019;218:123–127
16 January CT, Wann LS, Alpert JS, et al;ACC/AHA Task Force Mem-
bers. 2014 AHA/ACC/HRS guideline for the management of
patients with atrial fibrillation: executive summary: a report of
the American College of Cardiology/American Heart Association
Task Force on practice guidelines and the Heart Rhythm Society.
Circulation 2014;130(23):2071–2104
17 Kirchhof P, Benussi S, Kotecha D, et al;ESC Scientific Document
Group. 2016 ESC Guidelines for the management of atrial fibrilla-
tion developed in collaboration with EACTS. Eur Heart J 2016;37
(38):2893–2962
18 Schulman S, Kearon CSubcommittee on Control of Anticoagula-
tion of the Scientific and Standardization Committee of the
International Society on Thrombosis and Haemostasis. Definition
of major bleeding in clinical investigations of antihemostatic
medicinal products in non-surgical patients. J Thromb Haemost
2005;3(04):692–694
19 White IR, Royston P, Wood AM. Multiple imputation using
chained equations: Issues and guidance for practice. Stat Med
2011;30(04):377–399
20 Schomaker M, Heumann C. Bootstrap inference when using
multiple imputation. Stat Med 2018;37(14):2252–2266
21 Boriani G, Laroche C, Diemberger I, et al. Glomerular filtration rate
in patients with atrial fibrillation and 1-year outcomes. Sci Rep
2016;6:30271
22 EikelboomJW,Wallentin L, Connolly SJ, et al. Riskof bleedingwith 2
doses of dabigatran compared with warfarin in older and younger
patients with atrial fibrillation: an analysis of the randomized
evaluation of long-term anticoagulant therapy (RE-LY) trial. Circu-
lation 2011;123(21):2363–2372
23 Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of
dabigatran compared with warfarin in relation to baseline renal
function in patients with atrial fibrillation: a RE-LY (randomized
evaluation of long-term anticoagulation therapy) trial analysis.
Circulation 2014;129(09):961–970
24 Ramagopalan SV, Stamp E, Sammon CJ, et al. Renal function and
oral anticoagulant treatment of incident non-valvular atrial
fibrillation: a retrospective study. Future Cardiol 2019;15(04):
301–309
25 Steinberg BA, Holmes DN, Piccini JP, et al;Outcomes Registry for
Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Inves-
tigators and Patients. Early adoption of dabigatran and its dosing
in US patients with atrial fibrillation: results from the outcomes
registry for better informed treatment of atrial fibrillation. J Am
Heart Assoc 2013;2(06):e000535
26 Connolly SJ, Ezekowitz MD, Yusuf S, et al;RE-LY Steering Commit-
tee and Investigators. Dabigatran versus warfarin in patients with
atrial fibrillation. N Engl J Med 2009;361(12):1139–1151
TH Open Vol. 5 No. 1/2021 © 2021. The Author(s).
Anticoagulants and Renal Function in GLORIA-AF van der Wall et al.e42
